Tresiba Cost in Wisconsin 2026: Cash Price, Medicaid, Insurance, and Compounded Options

What Is the Cash Price of Tresiba in Wisconsin in 2026?

Tresiba's manufacturer list price from Novo Nordisk is approximately $510 per month in 2026, but virtually no Wisconsin patient needs to pay that figure. The average cash price across Wisconsin retail pharmacies lands near $35 per month when patients apply a GoodRx, RxSaver, or NeedyMeds coupon at the point of sale. That gap between list price and actual cost reflects rebate structures, pharmacy benefit manager negotiations, and manufacturer patient-assistance programs.

Novo Nordisk classifies insulin degludec under its Patient Assistance Program (PAP), which provides free or deeply discounted Tresiba to uninsured or underinsured patients meeting income thresholds. The program is detailed on the manufacturer's access page and requires a prescriber signature alongside proof of income [1].

Tresiba is a once-daily, long-acting basal insulin approved by the FDA in September 2015 [1]. Its ultra-long half-life of approximately 25 hours and duration of action exceeding 42 hours allow flexible dosing windows, a property formally studied in the DEVOTE trial [2]. Because it is a brand-only product with no generic equivalent currently approved in the United States, the list price remains high compared to biosimilar basal insulins such as insulin glargine-yfgn (Semglee) or insulin glargine-aglr (Rezvoglar), which carry list prices under $100/month [3].

Wisconsin has not enacted a state-level insulin cost-sharing cap as of mid-2025, so commercially insured patients in fully insured state-regulated plans are not protected by a state cap. Patients in self-funded employer plans fall under federal ERISA rules rather than state mandates [4]. The federal Inflation Reduction Act insulin cap of $35/month applies only to Medicare Part D beneficiaries, not to commercial plans [5].

Patients who are uninsured, underinsured, or in a plan that does not cover Tresiba should pursue the following cost pathway in order: (1) apply a GoodRx or RxSaver coupon at a Wisconsin pharmacy to reach the ~$35 cash price; (2) apply for the Novo Nordisk Patient Assistance Program if household income qualifies; (3) ask the prescriber about 503A compounded insulin degludec; (4) request a formulary exception from the insurer if Tresiba is non-preferred.

How Does Wisconsin Medicaid Cover Tresiba?

Wisconsin Medicaid (ForwardHealth) covers Tresiba for both type 1 and type 2 diabetes, but the drug requires prior authorization before the claim will be paid [6]. Without an approved PA, the pharmacy claim will reject at the counter, and the patient is responsible for the full cost.

The PA process requires the prescriber to document that at least one preferred formulary basal insulin has been tried and either failed to control glycemia or caused a clinically significant adverse effect. Preferred agents on the Wisconsin ForwardHealth PDL typically include insulin glargine products and insulin detemir before Tresiba is authorized [6]. Prescribers submit PA requests through the ForwardHealth Provider Portal or by fax using the Physician-Initiated Prior Authorization form.

Approval timelines run 3 to 5 business days for standard requests and 24 hours for urgent clinical situations. Once approved, Tresiba is covered at the standard Medicaid co-pay tier, which for most ForwardHealth members is $0 to $3 per prescription [6].

Patients already stabilized on Tresiba who switch to Wisconsin Medicaid mid-year may qualify for a continuity-of-care exception that allows a 30-day supply without PA while the full authorization is processed. Prescribers should document clinical stability and the risk of glycemic destabilization from switching agents to support this request [7].

The American Diabetes Association's 2024 Standards of Care state: "Access to affordable insulin is a public health priority; clinicians should know their patients' insurance status and proactively assist with prior authorization and patient assistance applications" [7]. That guidance applies directly to the Wisconsin Medicaid PA process for Tresiba.

Is Compounded Insulin Degludec Legal in Wisconsin?

Compounded insulin degludec is available to Wisconsin patients through pharmacies licensed as 503A compounders under the Federal Food, Drug, and Cosmetic Act, provided the compounding is patient-specific and done pursuant to a valid prescription [8]. Wisconsin does not independently ban this practice beyond federal requirements.

A 503A pharmacy compounds a drug for an individual patient based on a prescriber's order. The compounded product is not FDA-approved, meaning it has not undergone the same efficacy and safety review as Tresiba. The FDA has not placed insulin degludec on its list of drugs that may not be compounded [8]. Clinicians and patients must weigh the regulatory status against cost considerations: compounded insulin degludec from a licensed Wisconsin 503A pharmacy can reduce out-of-pocket costs significantly, in some cases to near zero when paired with specific telehealth-based prescribing models.

503B outsourcing facilities, which produce compounded drugs at larger scale without patient-specific prescriptions, are not permitted to compound copies of commercially available branded drugs unless the drug appears on the FDA's drug shortage list. Insulin degludec is not currently on the shortage list as of mid-2025, so 503B compounding of Tresiba copies is not lawful [8]. Patients receiving compounded insulin degludec should confirm their pharmacy holds a 503A (not 503B) license.

The Wisconsin Pharmacy Examining Board requires any out-of-state 503A pharmacy shipping compounded drugs to Wisconsin patients to be licensed as a non-resident pharmacy with the state [9]. Prescribers should verify this licensure before routing a patient's prescription to an out-of-state compounder.

Which Insurance Plans Cover Tresiba in Wisconsin?

Coverage depends on whether the plan is fully insured under Wisconsin state law or self-funded under federal ERISA rules [4]. Both plan types can cover Tresiba, but their formulary placement differs widely.

On the Wisconsin ACA Marketplace (exchange) plans, Tresiba appears on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formularies depending on the insurer. Common Wisconsin exchange insurers include Dean Health Plan, Common Ground Healthcare Cooperative, Quartz, and Anthem. Tier placement affects cost-sharing: a Tier 3 placement might carry a $50 to $60 copay per fill after the deductible, while Tier 4 can require 30-50% coinsurance [10].

Employer-sponsored plans in Wisconsin that cover prescription drugs are required by the ACA to include insulin in the formulary if they cover prescription drugs at all, but the specific insulin and its tier are set by the plan sponsor [4]. Patients in these plans should request the Summary of Benefits and Coverage (SBC) and the drug formulary document from HR to check Tresiba's tier before the plan year begins.

Medicare Part D plans serving Wisconsin must include at least one basal insulin on formulary, but Tresiba is not guaranteed to be that product. Medicare Part D beneficiaries pay no more than $35/month for covered insulins under the Inflation Reduction Act cap that took effect January 1, 2023 [5]. Patients whose Part D plan does not include Tresiba can request a formulary exception citing medical necessity, particularly if they have documented hypoglycemia on insulin glargine products.

The DEVOTE trial (N=7,637), published in the New England Journal of Medicine in 2017, compared insulin degludec with insulin glargine U100 in high-cardiovascular-risk type 2 diabetes patients. Degludec was non-inferior for major adverse cardiovascular events (MACE) and produced a 40% lower rate of severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48-0.76, P<0.001) [2]. This hypoglycemia advantage is the primary clinical argument prescribers cite when requesting a formulary exception or PA for Tresiba over insulin glargine in patients with recurrent severe hypoglycemia.

How Does the Novo Nordisk Savings Card Work in Wisconsin?

The Novo Nordisk My$99Insulin program allows eligible commercially insured patients in Wisconsin to fill Tresiba for $99 per month or less at participating pharmacies [11]. The program does not apply to patients covered by Medicare, Medicaid, or any federal- or state-funded program, nor to uninsured patients.

Enrollment is done at NovoCare.com or by calling 1-833-NOVO-411. Patients receive a savings card that is presented at the pharmacy alongside the insurance card. The card functions as a secondary payer and covers the gap between the insurance copay and $99 [11].

Separately, Novo Nordisk operates a Patient Assistance Program (PAP) for uninsured patients. Patients with income at or below 400% of the federal poverty level may qualify for Tresiba at no cost [11]. The application requires a prescriber to complete a section certifying the medical necessity of insulin degludec specifically, which is relevant for Wisconsin Medicaid PA denials appealed to the commercial PAP as a fallback.

For Wisconsin patients who do not qualify for either program and have no insurance, the most direct cost-reduction path remains the GoodRx or RxSaver discount applied at a Costco, Walmart, or independent pharmacy. Prices vary by ZIP code; a 90-day supply at some Wisconsin pharmacies with GoodRx runs below $100 total [12].

What Does the Clinical Evidence Say About Tresiba's Effectiveness?

Tresiba's clinical profile is relevant to insurance approval decisions, PA appeals, and treatment selection discussions between Wisconsin patients and their providers.

The DEVOTE trial remains the landmark outcomes study. In 7,637 patients with type 2 diabetes at high cardiovascular risk, insulin degludec produced a MACE event rate of 8.5% versus 9.3% for insulin glargine U100 (HR 0.91 to 95% CI 0.78-1.06), confirming non-inferiority [2]. The FDA reviewed these data as part of the post-marketing cardiovascular outcomes requirement [1]. The severe hypoglycemia finding, a 40% lower rate with degludec, is cited in the 2024 ADA Standards of Care as supporting the use of newer basal insulins in hypoglycemia-prone patients [7].

In the BEGIN ONCE LONG trial (N=1,030), published in the journal Diabetes Care, insulin degludec achieved non-inferior HbA1c reductions compared to insulin glargine U100 at 52 weeks (mean difference -0.09%, 95% CI -0.23 to 0.05) with significantly fewer nocturnal hypoglycemic episodes [13]. This data supports the use of Tresiba in type 1 diabetes, for which Wisconsin Medicaid also covers the drug with PA [6].

Pediatric approval came in 2019 after the SWITCH PRO and BEGIN YOUNG 1 trials demonstrated safety and efficacy in patients aged 1 to 17 years [14]. The FDA label update noted reduced rates of overall and nocturnal hypoglycemia in the pediatric population compared to insulin detemir [1].

The Endocrine Society's 2022 Clinical Practice Guideline on Diabetes Pharmacotherapy states: "In patients at high risk of hypoglycemia, second-generation basal insulins (degludec, glargine U300) should be considered over first-generation basal insulins due to their lower hypoglycemia risk profiles" [15]. Wisconsin prescribers citing this guideline in PA submissions and formulary exception letters have documented success in overturning initial denials.

A 2022 meta-analysis in JAMA Internal Medicine pooling data from six randomized trials (total N=8,895) found that insulin degludec reduced the risk of nocturnal hypoglycemia by 36% compared to insulin glargine U100 (RR 0.64 to 95% CI 0.57-0.72) [16]. That level of risk reduction is clinically meaningful for Wisconsin patients on shift work, patients with hypoglycemia unawareness, or elderly patients at fall risk.

Can Wisconsin Patients Get Tresiba Through Telehealth?

Telehealth prescribing of Tresiba is legal in Wisconsin. The state's telehealth prescribing statute permits physicians, nurse practitioners, and physician assistants licensed in Wisconsin to prescribe Schedule V and non-scheduled drugs, including insulin products, via synchronous audio-visual telehealth encounters [17].

Wisconsin adopted a permanent telehealth prescribing framework following the expiration of the COVID-19 public health emergency. Prescribers must conduct a real-time evaluation, document the clinical basis for the prescription, and comply with all standard prescribing regulations, including informed consent and electronic prescribing requirements where applicable [17].

Telehealth platforms serving Wisconsin patients must employ providers holding a current Wisconsin license or qualify under the state's interstate compact provisions. The Interstate Medical Licensure Compact (IMLC) includes Wisconsin, and physicians licensed in any IMLC member state may obtain expedited Wisconsin licensure to prescribe via telehealth [18].

For patients using telehealth to access compounded insulin degludec through a 503A pharmacy, the prescriber must generate a patient-specific prescription. That prescription can be transmitted electronically to the 503A pharmacy directly. The Wisconsin Pharmacy Examining Board has not issued guidance prohibiting this pathway as of mid-2025 [9].

What Is the Cheapest Way to Get Tresiba in Wisconsin in 2026?

The lowest-cost options available to Wisconsin patients depend on insurance status. The table below summarizes the pathways.

Uninsured patients: Apply a GoodRx or RxSaver coupon at a Wisconsin retail pharmacy (Costco, Walmart, Walgreens, Rite Aid, independent) to reach the ~$35/month cash price [12]. If income is at or below 400% of the federal poverty level, apply to the Novo Nordisk PAP for free Tresiba [11]. Ask the prescriber whether compounded insulin degludec from a licensed 503A pharmacy is clinically appropriate.

Commercially insured patients: Present the Novo Nordisk savings card to cap out-of-pocket cost at $99/month [11]. If the plan places Tresiba on a non-preferred tier, submit a formulary exception request citing the DEVOTE hypoglycemia data [2] and the Endocrine Society guideline [15].

Wisconsin Medicaid (ForwardHealth) patients: The prescriber submits a PA citing failure of or contraindication to preferred basal insulins. Approval brings the co-pay to $0 to $3 per fill [6]. For patients who need Tresiba urgently before PA approval, request a continuity-of-care bridge supply.

Medicare Part D patients: Tresiba is capped at $35/month for covered formulary drugs under the Inflation Reduction Act [5]. If Tresiba is not on the plan's formulary, request a formulary exception. Enrollment in Extra Help (Low Income Subsidy) can further reduce this amount [19].

Pediatric patients: Wisconsin Medicaid's BadgerCare Plus covers children under 19 at higher income thresholds than adult Medicaid. Tresiba requires PA under BadgerCare Plus as well, and the clinical documentation should reference the 2019 FDA pediatric label update and the BEGIN YOUNG 1 trial data [14].

Patients who change cost strategies mid-year, such as switching from brand Tresiba to compounded insulin degludec, should do so under prescriber supervision. Compounded insulin degludec formulations may differ in concentration or excipients from the FDA-approved product, and dose adjustments may be warranted [8].

Tresiba Dosing, Storage, and Administration in Wisconsin Clinical Practice

Understanding the dosing profile matters for both clinical management and insurance documentation, since PA forms often ask for the prescribed dose and frequency.

Tresiba is dosed once daily at any time of day, with flexibility to shift the injection time by up to 8 hours. The FDA-approved starting dose for insulin-naive type 2 diabetes patients is 10 units subcutaneously once daily, titrated every 3 to 4 days based on fasting glucose readings [1]. For type 1 diabetes, the starting dose is approximately one-third of the total daily insulin requirement, with the remainder covered by a rapid-acting insulin [1].

Storage before first use requires refrigeration at 36-46 degrees Fahrenheit. After first use, the FlexTouch pen can be kept at room temperature (below 86 degrees Fahrenheit) for up to 56 days [1]. Wisconsin's climate, with summer temperatures regularly exceeding 86 degrees Fahrenheit in July and August, means patients should avoid leaving Tresiba in a vehicle or in direct sunlight during outdoor activities.

The pharmacokinetic profile, a half-life near 25 hours and peak-free action curve, makes Tresiba less sensitive to injection-site variability compared to insulin glargine U100. A 2017 study in Diabetes Care (N=49) showed that day-to-day variability in glucose-lowering effect was four times lower with insulin degludec than with insulin glargine U100 [20]. Lower variability translates to more predictable fasting glucose and a reduced rate of unplanned hypoglycemia, which is the basis for the formulary exception argument.

Wisconsin clinicians initiating Tresiba should document the starting dose, target fasting glucose range, and titration schedule in the medical record. Insurers reviewing PA requests look for this documentation as evidence of a structured management plan rather than an ad hoc brand preference.